For instance, anti-VEGF antibodies may enhance the anti-tumor effects of HSV virotherapy via their anti-angiogenic effects and the modulation of the host inflammatory reaction against the virus [144], or they may enhance viral distribution as well as tumor hypoxia, achieving synergistic anti-breast cancer effects [145], although their administration prior to that of the virus may inhibit the tumor infection [138]. This evidence concerns the gene VEGFA and breast cancer.